Build-A-Bear to open multi-level store at Icon Park following Epic Universe debut
Editor's note: This story is available as a result of a content partnership between WFTV and the Orlando Business Journal.
Build-A-Bear Workshop (NYSE: BBW) will open a 'multi-level retail-tainment' store at Icon Park in 2026, according to a March 13 news release, growing its footprint at the International Drive center.
The iconic retailer's grand-scale expansion 'speaks volumes about the appeal of doing business in Orange County and at Icon Park,' said Icon Park President and CEO Chris Jaskiewicz in a prepared statement.
Read: Law enforcement paired with kids for 'Fishing with a cop' event at Long Lake
Sharon Price John, CEO of Build-A-Bear, said in the release the new Icon Park space will join other creative interpretations of Build-A-Bear's famous 'make your own' teddy bear retail concept.
Click here to read the full story on the Orlando Business Journal's website.
Click here to download our free news, weather and smart TV apps. And click here to stream Channel 9 Eyewitness News live.Sign in to access your portfolio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
CAE announces renewal of normal course issuer bid
MONTREAL, June 6, 2025 /CNW/ - (NYSE: CAE) (TSX: CAE) – CAE Inc. ("CAE") today announced that it has received regulatory approval to renew its normal course issuer bid ("NCIB") to purchase, for cancellation, up to 16,019,294 of its common shares commencing June 10, 2025 and ending June 9, 2026. The maximum number of common shares that may be repurchased under the program represents approximately five percent (5%) of the issued and outstanding common shares of CAE. The actual number of common shares purchased under the NCIB, the timing of purchases and the price at which the common shares are bought will depend upon management discretion based on factors such as market conditions. Purchases under the NCIB will be made through the facilities of the Toronto Stock Exchange ("TSX") in accordance with the TSX's applicable policies or the facilities of the New York Stock Exchange ("NYSE") in compliance with applicable NYSE rules and policies and U.S. laws, or in such other manner as may be permitted under applicable stock exchange rules and applicable securities laws, including through alternative Canadian and US trading platforms and privately-negotiated, off-exchange block purchases. In the case of off-exchange block purchases, purchases will be at a discount to the prevailing market price in accordance with and subject to the terms of applicable exemptive relief. RBC Dominion Securities Inc. ("RBC") has agreed to act as CAE's designated broker to make purchases of common shares pursuant to the NCIB. CAE has also entered into an automatic repurchase plan agreement ("ARPA") with RBC allowing it to purchase common shares under the NCIB when CAE would ordinarily not be permitted to purchase shares due to regulatory restrictions and customary self-imposed black-out periods. Before entering a black-out period, CAE may, but is not required to, instruct RBC to make purchases under the NCIB during such a period based on parameters set by CAE prior to the black-out period in accordance with the ARPA, TSX rules and applicable securities laws. All purchases made under the ARPA are included in computing the number of common shares purchased under the NCIB. The ARPA has been pre-cleared by the TSX and will be implemented and effective June 10, 2025, and will terminate on the earliest of the date on which: (i) the repurchase limit on the NCIB has been reached; (ii) the NCIB expires; (iii) CAE terminates the ARPA in accordance with its terms; and (iv) RBC terminates the ARPA in accordance with its terms. The ARPA constitutes an "automatic securities purchase plan" under applicable Canadian securities laws. The price CAE will pay for any common shares will be the market price at the time of acquisition, plus brokerage fees. During the period that the NCIB is outstanding, CAE does not intend to make purchases of its common shares other than by means of open market transactions or such other means as may be permitted or approved by any applicable securities regulator. The average daily trading volume of CAE's common shares through the facilities of the TSX over the last six completed calendar months was 733,845 ("ADTV"). Accordingly, under the TSX rules and policies, CAE will be entitled on any trading day to purchase up to 25% of the ADTV, which totals 183,461 common shares, for the next 12-month period of the NCIB. In excess of the daily repurchase limit, CAE may make, once per week, a block purchase (as such term is defined in the TSX Company Manual) of common shares not owned directly or indirectly by any insiders, which may exceed such daily limit, in accordance with the TSX rules. As of May 30, 2025, CAE had 320,385,889 common shares issued and outstanding. All common shares purchased pursuant to the NCIB will be cancelled. Under the normal course issuer bid which began on May 30, 2024, and which expired on May 29, 2025, CAE received approval from the TSX to purchase up to 15,932,187 common shares. As at May 29, 2025, CAE had purchased a total of 856,230 common shares thereunder, at a volume weighted average price of $24.85 per common share, for a total consideration of $21.3 million. Such purchases were effected through the facilities of the TSX and Canadian alternative trading systems. The NCIB is being established as part of CAE's capital allocation strategy. The Board of Directors of CAE believes that any purchases made under the NCIB will be in the best interest of CAE and that such purchases will constitute a desirable use of funds that should enhance shareholder value. About CAE At CAE, we exist to make the world safer. We deliver cutting-edge training, simulation, and critical operations solutions to prepare aviation professionals and defence forces for the moments that matter. Every day, we empower pilots, cabin crew, maintenance technicians, airlines, business aviation operators, and defence and security personnel to perform at their best and when the stakes are the highest. Around the globe, we're everywhere customers need us to be with approximately 13,000 employees at around 240 sites and training locations in over 40 countries. For nearly 80 years, CAE has been at the forefront of innovation, consistently seeking to set the standard by delivering excellence in high-fidelity flight simulators and training solutions, while embedding sustainability at the heart of everything we do. By harnessing technology and enhancing human performance, we strive to be the trusted partner in advancing safety and mission readiness—today and tomorrow. Caution concerning forward-looking statements This press release includes forward-looking statements, including in connection with CAE's NCIB, ARPA and future purchases of common shares pursuant to the NCIB. Since forward-looking statements and information relate to future events or future performance and reflect current expectations or beliefs regarding future events, they are typically identified by words such as "anticipate", "believe", "could", "estimate", "expect", "intend", "likely", "may", "plan", "seek", "should", "will", "strategy", "future" or the negative thereof or other variations thereon suggesting future outcomes or statements regarding an outlook. All such statements constitute "forward-looking statements" within the meaning of applicable Canadian securities legislation and "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. By their nature, forward‑looking statements require us to make assumptions and are subject to inherent risks and uncertainties associated with our business which may cause actual results in future periods to differ materially from results indicated in forward‑looking statements. While these statements are based on management's expectations and assumptions regarding historical trends, current conditions and expected future developments, as well as other factors that we believe are reasonable and appropriate in the circumstances, readers are cautioned not to place undue reliance on these forward-looking statements as there is a risk that they may not be accurate. The forward-looking statements contained in this press release describe our expectations as of June 6, 2025 and, accordingly, are subject to change after such date. Important risks that could cause such differences include, but are not limited to, those found in the Management's Discussion & Analysis for the year ended March 31, 2025. Specifically, there can be no assurance as to how many shares, if any, will ultimately be acquired under CAE's NCIB. Except as required by law, we disclaim any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. The forward-looking information and statements contained in this press release are expressly qualified by this cautionary statement. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this press release. While we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. Except as otherwise indicated by CAE, forward-looking statements do not reflect the potential impact of any special items or of any dispositions, monetizations, mergers, acquisitions, other business combinations or other transactions that may occur after June 6, 2025. The financial impact of these transactions and special items can be complex and depends on the facts particular to each of them. We therefore cannot describe the expected impact in a meaningful way or in the same way we present known risks affecting our business. Forward-looking statements are presented in this press release for the purpose of assisting investors and others in understanding certain key elements of CAE's NCIB. Readers are cautioned that such information may not be appropriate for other purposes. CAE Contacts: General Media:Samantha Golinski, Vice President, Public Affairs & Global Communications+1-438-805-5856, Investor Relations:Andrew Arnovitz, Senior Vice President, Investor Relations and Enterprise Risk Management,+1-514-734-5760, View original content: SOURCE CAE Inc. View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
29 minutes ago
- Business Wire
OS Therapies Submits Request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediatric Osteosarcoma
NEW YORK--(BUSINESS WIRE)-- OS Therapies Inc. (NYSE-A: OSTX) ('OS Therapies' or 'the Company'), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced it has submitted a request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the prevention of metastases in recurrent, fully-resected, lung metastatic pediatric osteosarcoma. RMAT designations are granted to sponsors with regenerative medicine therapies for serious or life-threatening conditions and provide sponsors with various benefits, including eligibility for an accelerated Biologics License Application (BLA) review. OST-HER2 has already received Rare Pediatric Disease Designation (RPDD), Orphan Drug Designation (ODD) and Fast Track Designation (FTD) for osteosarcoma from the U.S. FDA. If OST-HER2 receives a conditional BLA via Accelerated Review prior to September 30, 2026, the Company will become eligible to receive a Priority Review Voucher (PRV) that it intends to immediately sell. The most recent publicly disclosed PRV sale, valued at $155 million, occurred in May 2025. The Company is awaiting feedback by mid-June 2025 from a Type D meeting with FDA regarding the statistical analysis plan to be used in an End of Phase 2 meeting for OST-HER2 in the prevention of metastases in recurrent, fully-resected, lung metastatic pediatric osteosarcoma. Upon receipt of the Type D Meeting feedback, the Company intends to promptly request the End of Phase 2 meeting with FDA in which it will be seek agreement to allow it to begin a rolling BLA submission in the third quarter of 2025. The grant of the RMAT designation in the third quarter of 2025 complements the company's parallel efforts in other major markets, including Europe and the United Kingdom, where the company plans to seek EMA PRIME Designation and Conditional Market Access (CMA) applications. In parallel to regulatory engagement and market access planning for OST-HER2, the Company is preparing for the late stage clinical development of other pipeline candidates. As such, the Company is well positioned for sustained growth across multiple therapeutic modalities. About OS Therapies OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the U.S. Food & Drug Administration and Fast-Track and Orphan Drug designations from the U.S. FDA and European Medicines Agency. The Company has demonstrated positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a BLA to the U.S. FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma. In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as "anticipate," "expect," "intend," "may," "will," "should" or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the approval of OST-HER2 by the U.S. FDA and other risks and uncertainties described in 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in the Company's most recent Annual Report on Form 10-K and other subsequent documents the Company files with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Yahoo
34 minutes ago
- Yahoo
Best Stock to Buy Right Now: Target vs. RH
Target is struggling with weak sales, sending its shares sharply lower in 2025. RH's earnings outlook has been clouded by the looming impact of tariffs on its imported high-end home furnishings. One of these retail stocks may be poised to rebound in the second half of the year. 10 stocks we like better than RH › It's a matchup between two consumer goods retailers navigating a turbulent economic landscape. As of this writing, shares of Target (NYSE: TGT) are down 31% year to date amid disappointing sales. RH (NYSE: RH) stock has also missed the mark, falling 58% in 2025, facing concerns that its supply chain of imported high-end furniture and subsequent earnings outlook is exposed to new U.S. trade tariffs. Despite headwinds, Target and RH remain industry leaders, offering reasons for investor optimism about a potential turnaround. Could their recent stock price declines present a compelling buy-the-dip opportunity? Let's explore whether Target or RH is the best stock to buy now. Target stands out among its discount retail industry competitors, such as Walmart or Dollar General, by offering a more elevated in-store shopping experience. The retailer blends affordability with a curated assortment of merchandise, including a growing portfolio of private-label brands, attracting a loyal customer base. On the other hand, Target is facing a historically challenging period into 2025, with core shoppers cutting discretionary spending due to economic uncertainty. In the first quarter (ended April 30), net sales declined by 2.8% year over year, while adjusted earnings per share (EPS) of $1.30 marked a 36% decline from last year, and missed the consensus Wall Street estimate of $1.61. Management cited soft in-store demand and some early tariff-related cost pressures. The headline numbers lack confidence, but investors should focus on the bigger picture. Target has been ramping up promotional efforts with a shifting sales mix, offering lower-price point items to appeal to more value-conscious shoppers and drive store traffic. The company's digital strategy has been a bright spot, with e-commerce sales growing 4.7% from the prior-year quarter. Even with Target guiding for a low-single-digit decline in net sales this year, the business remains profitable, with a 2025 adjusted EPS target between $7 and $9. That's great news for investors thinking about the sustainability of Target's $1.12-per-share quarterly dividend, now yielding 4.8%, which is further supported by a solid balance sheet. In contrast, RH doesn't pay a regular dividend. With shares trading at just 12 times its 2025 projected EPS as a forward price-to-earnings (P/E) ratio, Target also offers good value next to RH, trading at a forward P/E of 16. Investors seeking high-yield portfolio income have a strong argument that Target is the better retail stock to buy today. RH is a category leader in premium home furnishings, offering luxury furniture and design services through its upscale galleries and membership model. The company benefits from strong brand recognition and a reputation for high-quality products. However, those goods, primarily sourced from Asia, make RH vulnerable to tariffs on imports. When the levies were first announced back in April, RH stock plunged by 40% in a single day. In response, RH issued a statement noting its efforts to diversify its supply chain and projecting optimism toward its long-term growth potential. While Wall Street analyst estimates for RH earnings this year have been revised lower in recent months, what hasn't changed is the underlying customer demand and growth momentum. RH capped off its fiscal 2024 fourth quarter (ended Feb. 1) with comparable net revenue growth of 18% year over year, alongside a 21% increase in EPS compared to the prior-year quarter. The expectation is for revenue to climb by 11% in 2025, with that outlook helping to justify RH's valuation premium next to Target. If tariff uncertainties resolve soon, possibly via trade negotiations, RH stock could rebound sharply. Investors who believe RH will emerge stronger and still on track for significant long-term growth as it expands internationally could consider buying the stock now. As tempting as Target's dividend yield is, I believe RH stock is the better buy today, since it may have more upside as its operating and financial conditions normalize. What I like about RH is that the company is unique in its scale and specialization within luxury home furnishings, while Target faces more intense direct competition. From its beaten-down price level, I predict shares of RH will outperform, led by its continued strong growth, making it a solid addition to diversified portfolios. Before you buy stock in RH, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and RH wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor's total average return is 789% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Dan Victor has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Target and Walmart. The Motley Fool recommends RH. The Motley Fool has a disclosure policy. Best Stock to Buy Right Now: Target vs. RH was originally published by The Motley Fool Sign in to access your portfolio
